Publication | Closed Access

Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

MedicineClinical TrialsPlaque PsoriasisClinical DermatologyParallel-group StudySkin PharmacologyPharmacotherapyDermatologyPharmacologyPhase 1